$14.94
-0.98-6.16%
Últ. Act.: Oct 2, 4:00 PM
$14.94
-0.98-6.16%
NovoCure (NVCR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
NovoCure (NVCR) publicó su última previsión de julio 23, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $710M - $725M para el período.
En comparación con la previsión anterior, NovoCure elevado redujo su previsión de ingresos desde un rango anterior de $690M - $710M.
NovoCure ha emitido 11 actualizaciones de orientación entre el enero 9, 2023 y el julio 23, 2026. During this period, the company raised its outlook 7 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.33 | $-0.49 | $-0.41 | $-0.42 |
| Actual | $-0.13 | $-0.62 | $-0.22 | $-0.33 |
| Surprise | +60.6% | -26.5% | +46.3% | +21.4% |
| Revenue | ||||
| Estimate | $172.6M | $167.8M | $173.2M | $158.3M |
| Actual | $183.6M | $174.1M | $174.3M | $167.2M |
| Surprise | +6.35% | +3.73% | +0.67% | +5.60% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.24 | $-0.24 | $-0.20 | $-0.16 |
| Revenue | ||||
| Consensus | $182.4M | $186.2M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 23, 2026 | $-0.13 | $-0.33 | 60.6 % |
| Q1 | Apr 30, 2026 | $-0.62 | $-0.49 | -26.5 % |
| Q4 | Feb 26, 2026 | $-0.22 | $-0.41 | 46.3 % |
| Q3 | Oct 30, 2025 | $-0.33 | $-0.42 | 21.4 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 23, 2026 | $183.58M | $172.62M | 6.35 % |
| Q1 | Apr 30, 2026 | $174.06M | $167.80M | 3.73 % |
| Q4 | Feb 26, 2026 | $174.35M | $173.18M | 0.67 % |
| Q3 | Oct 30, 2025 | $167.20M | $158.34M | 5.60 % |